Cyclacel Pharmaceuticals Inc (CYCC) — Financial Flexibility Index
Cyclacel Pharmaceuticals Inc (CYCC) has a Financial Flexibility Index of -1.37x as of June 2025. Free cash flow of $-1.06K (operating CF $-1.06K minus capex $0.00) represents -1% of total liabilities ($770.00). Check Cyclacel Pharmaceuticals Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Cyclacel Pharmaceuticals Inc Financial Flexibility Index (2003–2024)
Historical Financial Flexibility Index trend for Cyclacel Pharmaceuticals Inc across 22 annual periods. For the full cash flow conversion analysis, see Cyclacel Pharmaceuticals Inc cash flow conversion.
Annual Financial Flexibility Index for Cyclacel Pharmaceuticals Inc (2003–2024)
Year-by-year free cash flow to debt coverage for Cyclacel Pharmaceuticals Inc. Explore Cyclacel Pharmaceuticals Inc debt service capacity to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -1.27x | $-7.99 Million | $-7.99 Million | $6.27 Million | ▲ +35.1% |
| 2023 | -1.96x | $-16.11 Million | $-16.11 Million | $8.20 Million | ▲ +28.1% |
| 2022 | -2.73x | $-20.82 Million | $-20.83 Million | $7.62 Million | ▲ +19.6% |
| 2021 | -3.40x | $-18.51 Million | $-18.54 Million | $5.44 Million | ▼ -53.7% |
| 2020 | -2.21x | $-7.84 Million | $-7.93 Million | $3.54 Million | ▲ +15.3% |
| 2019 | -2.61x | $-9.44 Million | $-9.45 Million | $3.61 Million | ▼ -78.5% |
| 2018 | -1.46x | $-6.66 Million | $-6.70 Million | $4.55 Million | ▲ +16.9% |
| 2017 | -1.76x | $-7.47 Million | $-7.48 Million | $4.24 Million | ▲ +5.7% |
| 2016 | -1.87x | $-10.08 Million | $-10.08 Million | $5.39 Million | ▲ +23.2% |
| 2015 | -2.43x | $-14.43 Million | $-14.46 Million | $5.93 Million | ▼ -1.8% |
| 2014 | -2.39x | $-18.39 Million | $-18.70 Million | $7.70 Million | ▲ +0.4% |
| 2013 | -2.40x | $-17.99 Million | $-18.20 Million | $7.50 Million | ▼ -86.2% |
| 2012 | -1.29x | $-12.03 Million | $-12.04 Million | $9.34 Million | ▲ +40.1% |
| 2011 | -2.15x | $-13.97 Million | $-13.98 Million | $6.50 Million | ▲ +12.4% |
| 2010 | -2.45x | $-16.04 Million | $-16.04 Million | $6.54 Million | ▼ -58.8% |
| 2009 | -1.55x | $-15.18 Million | $-15.19 Million | $9.82 Million | ▲ +46.0% |
| 2008 | -2.86x | $-29.54 Million | $-29.91 Million | $10.31 Million | ▼ -140.5% |
| 2007 | -1.19x | $-21.37 Million | $-23.14 Million | $17.94 Million | ▲ +42.9% |
| 2006 | -2.08x | $-19.50 Million | $-20.17 Million | $9.36 Million | ▲ +30.8% |
| 2005 | -3.01x | $-20.61 Million | $-21.51 Million | $6.84 Million | ▼ -107.9% |
| 2004 | -1.45x | $-16.64 Million | $-21.09 Million | $11.48 Million | ▼ -733.3% |
| 2003 | -0.17x | $-14.49 Million | $-15.49 Million | $83.34 Million | — |